Inventor · disambiguated record
Shuqun Lin
Also filed as: LIN SHUQUN
18 granted patents·3 pending applications·266 citations·filing 1999–2024
94Inventor score
Files withBRISTOL MYERS SQUIBB CO13WROBLESKI STEPHEN T5TEXAS BIOTECHNOLOGY CORP2TEXAS BIOTECHNOLOGY CORP INC1
Top patents by PatentIndex Score
21 records- 0197US9505748B2Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responsesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Nov 29, 2016·53 cites·9 claims
- 0296US10000480B2Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 19, 2018·20 cites·14 claims
- 0396US7723336B2Fused heterocyclic compounds useful as kinase modulatorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted May 25, 2010·50 cites·16 claims
- 0494USRE47929EAmide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responsesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Apr 7, 2020·19 cites·39 claims
- 0592US10526321B2Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 7, 2020·6 cites·1 claims
- 0688US9315494B2Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responsesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Apr 19, 2016·14 cites·11 claims
- 0787US2025243193A1Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0881US6194448B1N, N-disubstituted amides that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Feb 27, 2001·42 cites·17 claims
- 0977US7935696B2Heterocyclic amide compounds useful as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted May 3, 2011·2 cites·9 claims
- 1077US7923556B2Phenyl-substituted pyrimidine compounds useful as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Apr 12, 2011·2 cites·10 claims
- 1176US7642257B2Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Jan 5, 2010·2 cites·13 claims
- 1276US2022356180A1Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responsesBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1374US6096773ACompounds that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP INC·Filed 1999·Granted Aug 1, 2000·33 cites·10 claims
- 1470US8987268B2Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesWROBLESKI STEPHEN T·Filed 2012·Granted Mar 24, 2015·2 cites·14 claims
- 1566US7419978B2Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Sep 2, 2008·2 cites·10 claims
- 1666US6262084B1Compounds that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Jul 17, 2001·18 cites·10 claims
- 1764US9221826B2Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesWROBLESKI STEPHEN T·Filed 2012·Granted Dec 29, 2015·1 cites·10 claims
- 1849US8404689B2Heterocyclic amide compounds useful as kinase inhibitorsWROBLESKI STEPHEN T·Filed 2011·Granted Mar 26, 2013·0 cites·15 claims
- 1949US2006178388A1Phenyl-substituted pyrimidine compounds useful as kinase inhibitorsWROBLESKI STEPHEN T·Filed 2006·Application pending·0 cites
- 2042US10308652B2Tricyclic heterocyclic compounds useful as inhibitors of TNFBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 4, 2019·0 cites·3 claims
- 2138US8921368B2Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesWROBLESKI STEPHEN T·Filed 2012·Granted Dec 30, 2014·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Shuqun Lin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →